News article on the Series A round and the involvement of prominent global biotech investors Greg Bailey and Jim Mellon. Features quotes from Marc Wayne, Chairman of Board.
News article on the Series A round featuring an interview with CEO, Cosmo Feilding Mellen, discussing optimism around drug regulation and encouraging data for psychedelic medicine.
Beckley Psytech has raised £3m to turn psychedelic compounds into depression treatments.
The FT’s daily tech newsletter covers the news of the Series A round, highlighting Richard Reed’s investment and the ambitions for the company in treating depression and addiction.